Octreotide的131I标记及Graves 眼病炎症细胞的体外摄取

doi:10.7538/tws.2011.24.02.0094

同位素 ›› 2011, Vol. 24 ›› Issue (2): 94-97.DOI: 10.7538/tws.2011.24.02.0094

• 放射性药物和标记化合物 • 上一篇下一篇

Octreotide的¹³¹I标记及Graves 眼病炎症细胞的体外摄取

卢霞¹;王荣福¹;闫平¹;周颖明²;张一帆²

1.北京大学第一医院核医学科，北京100034；2. 上海交通大学医学院附属瑞金医院眼科，上海200025

收稿日期:1900-01-01 修回日期:1900-01-01 出版日期:2011-05-20 发布日期:2011-05-20

Labeling of Octreotide With ¹³¹I and Its Vitro Uptake in Inflammatory Cells for Graves’ Ophthalmopathy

LU Xia¹;WANG Rong-fu¹;YAN Ping¹;ZHOU Ying-ming²;ZHANG Yi-fan²

1. Department of Nuclear Medicine, Peking University First Hospital， Beijing 100034, China；2. Departmen of Ophthalmology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine， Shanghai 200025, China

Received:1900-01-01 Revised:1900-01-01 Online:2011-05-20 Published:2011-05-20

摘要/Abstract

摘要： 将octreotide中的苯丙氨酸用酪氨酸替换合成[Tyr₃]octreotide，对其进行了¹³¹I标记。考察了氯胺T标记法中氯胺T和[Tyr₃]octreotide的用量对标记率的影响，观察了Graves眼病相关炎症细胞对¹³¹I-[Tyr₃]octrotide 的体外摄取情况。结果表明，对octreotide进行结构修饰后得到的[Tyr₃]octreotide可以用于¹³¹I标记；氯胺T法对[Tyr₃]octreotide进行¹³¹I标记时，氯胺T和[Tyr₃]octreotide的最佳用量分别为1.6和1.4 μg，最高标记率为85%；T淋巴细胞、活化的成纤维细胞及血管内皮细胞均能够摄取¹³¹I-[Tyr₃]octreotide，而脂肪细胞的摄取则明显较少。以上结果表明，¹³¹I-[Tyr₃]octreotide能够被Graves眼病发病过程中的炎症细胞摄取，具有用于Graves眼病发病过程中炎症反应程度评估的应用潜力。但由于摄取量还很小，需要进一步深入研究。

关键词: ¹³¹I, octreotide, 标记, Graves眼病, 炎症细胞

Abstract: Phenylalanine was displaced by tyrosine in octreotide([Tyr₃]octreotide) to study the labeling methods of [Tyr₃]octreotide with ¹³¹I，and the difference uptake ability of ¹³¹I-[Tyr₃]octreotide in various cell lines of Graves ophthalmopathy were observed. The results showed that [Tyr₃]octreotide could be labeled with ¹³¹I by chloramines-T method and the optimal conditiona was 1.6 μg chloramines-T and 1.4 μg [Tyr₃]octreotide. The labeling efficiency was 85%. T lymphocyte, fibroblast, and HUVEC could accumulate ¹³¹I-[Tyr₃]octreotide largely compared to lipocyte, which indicated that ¹³¹I-[Tyr₃]octreotide could be combined with inflammatory cells in Graves’ ophthalmopathy.

Key words: ¹³¹I, octreotide, labeling, Graves’ ophthalmopathy, inflammatory cells

卢霞 ;王荣福 ;闫平 ;周颖明 ;张一帆 . Octreotide的¹³¹I标记及Graves 眼病炎症细胞的体外摄取[J]. 同位素, 2011, 24(2): 94-97.

LU Xia;WANG Rong-fu;YAN Ping;ZHOU Ying-ming;ZHANG Yi-fan. Labeling of Octreotide With ¹³¹I and Its Vitro Uptake in Inflammatory Cells for Graves’ Ophthalmopathy[J]. Journal of Isotopes, 2011, 24(2): 94-97.

[1]	黄伟, 陈宝军, 赵思倩. ³H与¹⁴C放射性标记化合物发展现状[J]. 同位素, 2021, 34(2): 175-180.
[2]	赵海龙;李洪玉. 肿瘤诊断⁶⁴Cu标记药物临床研究进展[J]. 同位素, 2021, 34(1): 78-88.
[3]	余凯翔;杨征敏;周兵;徐凌锋;李书琰;陈沪飞;王伟. 放射性同位素碳-14标记毒死蜱的合成与分析[J]. 同位素, 2020, 33(6): 409-416.
[4]	黄旭虎;李洪玉. 放射性核素标记耐久霉素细胞凋亡显像的研究进展[J]. 同位素, 2020, 33(6): 435-442.
[5]	邱婷;张曙盛;朱苏珍;郭寅龙. 稳定同位素D标记甜蜜素的合成[J]. 同位素, 2020, 33(5): 273-278.
[6]	孙雯;李杰;杜晓宁;徐仲杰;潘洁;尤雅芳;李美华. 邻苯二甲酸酯类标准物质在婴幼儿乳粉塑化剂检测中的应用研究[J]. 同位素, 2020, 33(5): 279-285.
[7]	周明;李玉来;杨能安;李建;陈小娟;胡硕. ［¹⁸F］-苯丙氟硼酸的制备工艺改进及初步临床应用[J]. 同位素, 2020, 33(3): 167-172.
[8]	涂亚辉;邓晓军;钟佳琪;赵超敏;罗勇;潘洁;徐仲杰. 稳定同位素标记甲基毒死蜱-D₆的合成研究[J]. 同位素, 2020, 33(3): 173-179.
[9]	邵武国;郭宏利;秦红斌;马红利. 高精度放射性药液自动分装系统的研制[J]. 同位素, 2019, 32(6): 395-402.
[10]	侯静华;刘占峰;杜晓宁;宋明鸣. 发酵优化制备L-赖氨酸盐酸盐-¹³C₆、¹⁵N₂[J]. 同位素, 2019, 32(6): 418-424.
[11]	刘轩;景士伟;李明非;郑彦;高亚东;年瑞雪. 基于标记中子方法的爆炸物特征γ能谱分析[J]. 同位素, 2019, 32(5): 309-314.
[12]	郭志德;张现忠;杜进. ⁶⁸Ga标记药物研究进展[J]. 同位素, 2019, 32(5): 360-374.
[13]	张晓军;付华平;李云钢;刘健;崔孟超;富丽萍;张锦明. Tau蛋白显像剂¹⁸F-THK5317的合成与初步临床应用[J]. 同位素, 2019, 32(2): 121-127.
[14]	赵禹;刘向红;张玉龙;李海颖. 医用同位素生产堆应急停堆系统设计研究[J]. 同位素, 2019, 32(2): 128-132.
[15]	刘炳楠;熊利平;姜申德;要少波. 16-表雌三醇的合成及放射性标记[J]. 同位素, 2018, 31(5): 283-290.

Octreotide的¹³¹I标记及Graves 眼病炎症细胞的体外摄取

Labeling of Octreotide With ¹³¹I and Its Vitro Uptake in Inflammatory Cells for Graves’ Ophthalmopathy

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics